Posts by Sandra Ansanay-Alex
Robert Wenner Prize: Two Cancer Researchers Honoured
The Robert Wenner Prize, which recognises scientists in the field of cancer research, is being awarded this year for the first time to two female researchers: Professor Michal Bassani-Sternberg (University of Lausanne/CHUV) and Professor Camilla Jandus (University of Geneva). The Swiss Cancer League is honouring both for their pioneering work in the field of immunotherapy.…
Read MoreMindmaze joins forces with Vibra Healthcare to bring its neurotherapies to the United States
After first announcing a partnership in 2022, the Lausanne-based neurotech company aims to speed up the launch of its digital neurological rehabilitation solutions on the US market using the Vibra Healthcare network and know-how. MindMaze Therapeutics, a pioneer in advanced neurotherapeutic technologies, and Vibra Healthcare, a leading provider of neurological care and rehabilitation services, announced…
Read MoreFORUM Phage Therapy
The Forum Phage Therapy is taking place on 30 May 2026 in Lausanne with experts from UNIL, CHUV, EPFL and UNIGE Antibiotic-resistant microorganisms are a problem for the healthcare sector. Phage therapy is a method that uses viruses, specifically phages, which are capable of attacking and destroying targeted bacteria. It can be used as a…
Read MoreSDSC and Canton of Vaud Support Bewe Lab and Perivision
Bewe Lab and Perivision are among the four companies selected by Canton de Vaud and the Swiss Data Science Center (SDSC) to join a new programme to help companies boost their projects with artificial intelligence and data science. The goal is to establish artificial intelligence as a key part of the Vaud economy. Bewe Lab:…
Read MoreImmitra Bio Receives a CHF 150,000 Gebert Rüf Stiftung InnoBooster Grant
Geneva-based startup Immitra Bio has been selected as one of the latest winners of the InnoBooster programme, supported by the Gebert Rüf Stiftung. This CHF 150,000 grant will be used to build a scalable in-vivo gene-editing platform to make genetic therapies accessible to all patients, regardless of where they live or their financial means. Founded…
Read MoreHAS Healthcare Advanced Synthesis Group Announces Strategic Investments in Biodelphis Therapeutics
HAS Healthcare Advanced Synthesis (Ticino) and Biodelphis Therapeutics (Vaud) announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases. This collaboration combines HAS Group long‑standing expertise in complex bioconjugation, process development, and clinical‑grade manufacturing…
Read MoreIFF Awards
Apply until 30 June 2026 for the IFF (Innovation Fribourg Freibourg) Awards, a initiative of Canton of Fribourg to honor promising and innovative companies. The IFF 2026–2027 Award (Innovation Fribourg Freiburg) has officially launched its 18th call for applications, reaffirming its commitment to supporting innovation across the canton. With a total prize fund of CHF…
Read MoreMoonlight AI AG Raises $3.3M Seed Round
Moonlight AI AG, a Swiss startup building image analysis software for clinical-grade diagnostics, has closed a $3.3 million USD Seed round. The investment was co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland), and MEDIN Fund (Tunisia), with participation from N&V Capital (Liechtenstein) and existing investor QAI Ventures (Switzerland). Turning routine slide images into…
Read MoreSwiss Biotech on the Rise: Strong Momentum in 2025
Switzerland’s biotech sector continues to demonstrate remarkable resilience and growth, even in a complex global environment. According to the latest Swiss Biotech Report 2026, the industry reached new heights in 2025—both in terms of revenue and investment—further strengthening the country’s position as a global life sciences powerhouse. Record performance in a challenging context The numbers…
Read MoreBayer – Co.Lab
Apply before 15 June 2026 for the Bayer Co.Lab programme. Get up to CHF 50,000 and personalised coaching If you’re an early-stage life science start-up company in Switzerland with that next great idea, then Bayer Co.Lab Connect Basel can offer you the opportunity you need to succeed. Bayer Co.Lab Connect Basel provides startups with a…
Read More